Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2008;39:e6
Published online before print November 29, 2007, doi: 10.1161/STROKEAHA.107.499673
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/1/e6    most recent
STROKEAHA.107.499673v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montaner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montaner, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Medline Plus Health Information
*Stroke

(Stroke. 2008;39:e6.)
© 2008 American Heart Association, Inc.


Letters to the Editor

Cholesterol Measured Before Stroke Thrombolysis Is Not Associated With Tissue Plasminogen Activator–Related Hemorrhagic Transformation

Joan Montaner, MD, PhD

Neurovascular Research Laboratory, Neurology Department, Vall d’Hebron Hospital, Barcelona, Spain

To the Editor:

A link between cholesterol level and symptomatic hemorrhagic transformation (sHT) after ischemic stroke thrombolysis has been recently described.1 This association might be relevant regarding use of statins in the acute stroke field. Bang et al defined sHT as any clinical worsening associated with HT, either major or minor. In that study any sHT appeared in 17 cases (16.4%). Low LDL cholesterol and previous treatment with statins were related to sHT appearance, and after adjusting for covariates low LDL cholesterol (odds ratio, 0.968 per 1-mg/dL increase; 95% CI, 0.941 to 0.995) was independently associated with sHT risk.

Similar to that study and to evaluate whether stroke patients who receive tissue plasminogen activator (t-PA) have different outcome when statins were taken before stroke, we evaluated 145 patients with a stroke involving the middle cerebral artery who received t-PA treatment.2 In our study, a logistic regression model identified previous treatment with statins (odds ratio 5.26; 95% CI, 1.48 to 18.72; P=0.027) as independent predictor of good functional outcome and no differences for any sHT regarding statin use was found (8.3% sHT among those receiving statins versus 9.3% sHT among those who did not receive statins, P=0.88).

Moreover, we have measured lipids profile in the plasma of 60 stroke patients before (<3 hours from stroke onset) they received t-PA treatment. Among them, 8.3% had any sHT; however, as shown in the the Table none of the measured lipidic parameters was related with that complication (Table). Similarly, any association was found when considering other HT classifications, such as parenchymal hematomas appearance (data not shown).


View this table:
[in this window]
[in a new window]

 
Table. t-PA–Related Hemorrhagic Transformation Regarding Lipidic Profile

In Bang et al’s study all patients had fasting lipid panels drawn the day after hospital admission; therefore, in many cases it is possible that the lipid profile was obtained after the hemorrhagic complication. Whether low LDL is a consequence and not the cause of the complication in their patients is a possibility. This was avoided in our study by measuring lipids before t-PA treatment.

Because high rates of sHT in Bang et al’s study (16.4% versus 8.3% in our patients) may be influenced by the use of mechanical devices, it might be interesting to know whether the cholesterol-sHT relationship they found was also true for the subgroups of patients that received only t-PA treatment. In my opinion cholesterol level measured before stroke thrombolysis is not associated with t-PA–related hemorrhagic transformation. In the future, more information coming from acute stroke trials that combine statins with t-PA might show new data on this interesting question.3

Acknowledgments

Disclosures

None.

References

1. Bang OY, Saver JL, Liebeskind DS, Starkman S, Villablanca P, Salamon N, Buck B, Ali L, Restrepo L, Vinuela F, Duckwiler G, Jahan R, Razinia T, Ovbiagele B. Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis. Neurology. 2007; 68: 737–742.[Abstract/Free Full Text]

2. Alvarez-Sabin J, Huertas R, Quintana M, Rubiera M, Delgado P, Ribo M, Molina CA, Montaner J. Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator. Stroke. 2007; 38: 1076–1078.[Abstract/Free Full Text]

3. Montaner J. Treatment with statins in the acute phase of ischemic stroke. Expert Rev Neurother. 2005; 5: 211–221.[Medline] [Order article via Infotrieve]




This article has been cited by other articles:


Home page
StrokeHome page
N. Meier, K. Nedeltchev, C. Brekenfeld, A. Galimanis, U. Fischer, O. Findling, L. Remonda, G. Schroth, H. P. Mattle, and M. Arnold
Prior Statin Use, Intracranial Hemorrhage, and Outcome After Intra-Arterial Thrombolysis for Acute Ischemic Stroke
Stroke, May 1, 2009; 40(5): 1729 - 1737.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
R. R. Ratan and M. Noble
Novel Multi-Modal Strategies to Promote Brain and Spinal Cord Injury Recovery
Stroke, March 1, 2009; 40(3_suppl_1): S130 - S132.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/1/e6    most recent
STROKEAHA.107.499673v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Montaner, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Montaner, J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CHOLESTEROL
Medline Plus Health Information
*Stroke